AngioDynamics
ANGONASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $12.07 Prior regular-session close from the quote source.
- $12.06–$12.43 Regular-session low and high so far today.
- 441.3K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Jan 5 projected Projected for 2027-01-05 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $9.39–$16.29 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own ANGO if its cardiovascular and cancer treatment devices regain adoption while management converts improved gross profit into self-funding cash flow.
ANGO price history
Loading recent earnings…
Investment thesis
What must happen next
Clinician adoption of AngioDynamics' cardiovascular and cancer treatment technologies continues to overcome hospital purchasing friction and larger device-company competition, allowing the business to rebuild demand.HoldingMateriality: High
GAAP annual revenue increased to $320.2 million in FY2026 from $292.5 million in FY2025. If adoption is real, the company has a revenue base to scale; if it is not, cost cuts alone cannot create durable equity value.
Watch: Hospitals standardize purchasing around broader device suppliers' bundled portfolios, reducing willingness to adopt AngioDynamics' specialized products.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased to $320.2 million in FY2026 from $292.5 million in FY2025.
Open source ↗Specialized med-tech product mix and manufacturing execution continue to support gross-profit expansion rather than forcing AngioDynamics to buy growth through discounting.StrengtheningMateriality: High
GAAP annual gross profit rose to $174.9 million in FY2026 from $157.7 million in FY2025. Revenue growth only creates value if product mix and pricing protect gross profit; otherwise scale may not close the operating-loss gap.
Watch: Group purchasing organizations or hospitals demand price concessions that offset volume growth.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit rose to $174.9 million in FY2026 from $157.7 million in FY2025.
Open source ↗Management's cost structure and commercial spending discipline become sufficient to convert rising gross profit into positive GAAP operating income.WeakeningMateriality: Medium
GAAP annual operating loss narrowed sharply to $39.9 million in FY2026 from $192.4 million in FY2024. This is the bridge from a promising product portfolio to equity value; without operating leverage, the company remains a loss-making med-tech platform.
Watch: The company must increase selling, clinical education, or R&D spending materially to defend adoption against larger competitors.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss narrowed sharply to $39.9 million in FY2026 from $192.4 million in FY2024.
Open source ↗Working-capital discipline and reduced cash burn give AngioDynamics enough financial runway to fund the turnaround without unfavorable capital raising.StrengtheningMateriality: Medium
GAAP annual operating cash flow improved to positive $3.1 million in FY2026 from negative $10.1 million in FY2025 and negative $28.2 million in FY2024. If the business can self-fund, shareholders keep the upside from the recovery; if cash burn resumes, dilution or strategic compromise becomes a real risk.
Watch: Inventory builds because demand for key products falls short of plan.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow improved to positive $3.1 million in FY2026 from negative $10.1 million in FY2025 and negative.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Clinician adoption of AngioDynamics' cardiovascular and cancer treatment technologies continues to overcome hospital purchasing friction and larger device-company competition, allowing the business to rebuild demand. If adoption is real, the company has a revenue base to scale; if it is not, cost cuts alone cannot create durable equity value.
Specialized med-tech product mix and manufacturing execution continue to support gross-profit expansion rather than forcing AngioDynamics to buy growth through discounting. Revenue growth only creates value if product mix and pricing protect gross profit; otherwise scale may not close the operating-loss gap.
Management's cost structure and commercial spending discipline become sufficient to convert rising gross profit into positive GAAP operating income. This is the bridge from a promising product portfolio to equity value; without operating leverage, the company remains a loss-making med-tech platform.
Working-capital discipline and reduced cash burn give AngioDynamics enough financial runway to fund the turnaround without unfavorable capital raising. If the business can self-fund, shareholders keep the upside from the recovery; if cash burn resumes, dilution or strategic compromise becomes a real risk.
All standing thesis claims
Original report summary
its cardiovascular and cancer treatment devices regain adoption while management converts improved gross profit into self-funding cash flow.
Bull case and bear case
Bull case and bear case for Angiodynamics
Where the evidence on Angiodynamics disagrees: Mixed on the latest evidence (Oct 16, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
Clinician adoption of AngioDynamics' cardiovascular and cancer treatment technologies continues to overcome hospital purchasing friction and larger device-company competition, allowing the business to rebuild demand.
Specialized med-tech product mix and manufacturing execution continue to support gross-profit expansion rather than forcing AngioDynamics to buy growth through discounting.
Working-capital discipline and reduced cash burn give AngioDynamics enough financial runway to fund the turnaround without unfavorable capital raising.
Bear case: what the evidence questions
Management's cost structure and commercial spending discipline become sufficient to convert rising gross profit into positive GAAP operating income.
Thesis-Break Engine
Thesis-break watch · Angiodynamics
Loading the break-condition record for Angiodynamics.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Angiodynamics filed an SEC 8-K on 2026-10-08: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Angiodynamics filed an SEC 8-K on 2026-10-08: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Angiodynamics filed an SEC 8-K on 2026-07-14: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Hospitals standardize purchasing around broader device suppliers' bundled portfolios, reducing willingness to adopt AngioDynamics' specialized products.
- Group purchasing organizations or hospitals demand price concessions that offset volume growth.
- The company must increase selling, clinical education, or R&D spending materially to defend adoption against larger competitors.
- Inventory builds because demand for key products falls short of plan.
ANGO news
Loading headlines…
Financial statements
ANGO income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ANGO: quick answers
- When does Angiodynamics (ANGO) report earnings next?
- Angiodynamics's next results are projected for January 5, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on October 8, 2026. Earnings calendar
- What is ANGO's short interest?
- As of October 30, 2026, 2.0M ANGO shares were sold short, 4.76% of its shares outstanding, up 4.5% from the count before. At the stock's average daily volume that is 2.9 days to cover. FINRA publishes the count twice a month. ANGO short interest history
- Have members of Congress traded ANGO?
- 6 trades in ANGO have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed ANGO trade